 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...89101112131415161718...2223» |
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Jul 18, 2019
P3, N=200, Suspended, Sponsor: Academic and Community Cancer Research United
Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Enrollment change: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Jul 18, 2019
P2, N=232, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019 N=138 --> 232
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 16, 2019
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
N=138 --> 232 Trial completion date: Mar 2019 --> Jul 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 15, 2019
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2019 --> Jul 2019 Active, not recruiting --> Completed
- | paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial initiation date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Jul 8, 2019
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Mar 2022 | Initiation date: Sep 2019 --> Dec 2019 | Trial primary completion date: Mar 2021 --> Jun 2021
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 8, 2019
P2, N=118, Completed, Sponsor: Asan Medical Center
Trial completion date: Dec 2021 --> Mar 2022 | Initiation date: Sep 2019 --> Dec 2019 | Trial primary completion date: Mar 2021 --> Jun 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019
- || Enrollment open, PD(L)-1 Biomarker: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 5, 2019
P1, N=24, Recruiting, Sponsor: Presage Biosciences
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 Active, not recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Trial suspension, PD(L)-1 Biomarker, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Jul 2, 2019
P2, N=78, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Recruiting --> Suspended
- ||| Talzenna (talazoparib) / Pfizer
Trial completion date, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Jun 25, 2019
P3, N=431, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Suspended Trial completion date: Sep 2019 --> Sep 2020
- |||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial primary completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 19, 2019
P3, N=345, Recruiting, Sponsor: Synthon Biopharmaceuticals BV
Trial completion date: Sep 2019 --> Sep 2020 Trial primary completion date: May 2019 --> Jul 2020
- |||||| balixafortide (POL 6326) / Spexis
Enrollment open, Combination therapy, Metastases: FORTRESS: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 18, 2019
P3, N=384, Recruiting, Sponsor: Polyphor Ltd.
Trial primary completion date: May 2019 --> Jul 2020 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Jun 18, 2019
P2, N=32, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2020
- || Halaven (eribulin mesylate) / Eisai
Enrollment change: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 12, 2019
P=N/A, N=256, Completed, Sponsor: Eisai Co., Ltd.
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2020 N=160 --> 256
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jun 7, 2019
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
N=160 --> 256 Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2018 --> Jun 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment open: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 6, 2019
P2, N=57, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2018 --> Jun 2020 Not yet recruiting --> Recruiting
- ||||| Margenza (margetuximab-cmkb) / MacroGenics
Enrollment closed: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Jun 4, 2019
P3, N=624, Active, not recruiting, Sponsor: MacroGenics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (clinicaltrials.gov) - May 28, 2019
P1, N=9, Active, not recruiting, Sponsor: Amy Tiersten
Recruiting --> Active, not recruiting Trial primary completion date: May 2019 --> May 2020
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - May 24, 2019
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: May 2019 --> May 2020 Trial completion date: Apr 2019 --> Dec 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion date: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - May 20, 2019
P2, N=162, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Apr 2019 --> Dec 2019 Trial completion date: Aug 2019 --> Aug 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - May 14, 2019
P3, N=622, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Aug 2019 --> Aug 2020 Trial completion date: Apr 2019 --> Aug 2020
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: ReProLine: Retroprospective Real Life Observatory of Eribulin (clinicaltrials.gov) - May 9, 2019
P=N/A, N=753, Completed, Sponsor: Institut Cancerologie de l'Ouest
Trial completion date: Apr 2019 --> Aug 2020 Recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Enrollment open, Monotherapy: REVERT: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (clinicaltrials.gov) - May 9, 2019
P2, N=60, Recruiting, Sponsor: MedSIR
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment open: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Apr 29, 2019
P3, N=400, Recruiting, Sponsor: Immunomedics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Apr 24, 2019
P2, N=32, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2019 --> Dec 2021
- | New trial: Breast Cancer Treatment Based on Organ-like Culture (clinicaltrials.gov) - Apr 23, 2019
P, N=300, Enrolling by invitation, Sponsor: Xijing Hospital
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 19, 2019
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2019 --> Dec 2021 Trial primary completion date: Dec 2019 --> Mar 2019
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Apr 18, 2019
P2, N=44, Active, not recruiting, Sponsor: MedSIR
Trial primary completion date: Dec 2019 --> Mar 2019 Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2018
- || Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 17, 2019
P1, N=12, Active, not recruiting, Sponsor: Amy Tiersten
Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2018 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2019
P2, N=32, Active, not recruiting, Sponsor: Virginia G. Kaklamani
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial initiation date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Apr 5, 2019
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Mar 2019 --> Dec 2019 Trial completion date: May 2021 --> Dec 2021 | Initiation date: Apr 2019 --> Sep 2019
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
New P3 trial: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Apr 3, 2019
P3, N=400, Not yet recruiting, Sponsor: Immunomedics, Inc.
- || Enrollment closed, Enrollment change, PD(L)-1 Biomarker: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 2, 2019
P1, N=24, Active, not recruiting, Sponsor: Presage Biosciences
Trial completion date: May 2021 --> Dec 2021 | Initiation date: Apr 2019 --> Sep 2019 Recruiting --> Active, not recruiting | N=12 --> 24
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
New P2 trial: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 2, 2019
P2, N=57, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Enrollment open, Trial completion date, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Mar 19, 2019
P=N/A, N=35, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting | N=12 --> 24 Suspended --> Recruiting | Trial completion date: Feb 2019 --> Jun 2021 | Trial primary completion date: Feb 2019 --> Jun 2020
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=160, Completed, Sponsor: Eisai Co., Ltd.
Suspended --> Recruiting | Trial completion date: Feb 2019 --> Jun 2021 | Trial primary completion date: Feb 2019 --> Jun 2020 Active, not recruiting --> Completed
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 11, 2019
P4, N=200, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=83 --> 200 | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Feb 2019 --> Aug 2019
- | Halaven (eribulin mesylate) / Eisai
Trial initiation date, Monotherapy: REVERT: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (clinicaltrials.gov) - Mar 7, 2019
P2, N=60, Not yet recruiting, Sponsor: MedSIR
Recruiting --> Active, not recruiting | N=83 --> 200 | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Feb 2019 --> Aug 2019 Initiation date: Jan 2019 --> Apr 2019
- | Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 1, 2019
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2019 --> Apr 2019 Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed: SAKK 25/14: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer (clinicaltrials.gov) - Mar 1, 2019
P2, N=77, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Feb 28, 2019
P1/2, N=21, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Feb 27, 2019
P1b/2, N=14, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2018 --> Jun 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change: Study of Eribulin in Children With Cancer to Determine Safety (clinicaltrials.gov) - Feb 26, 2019
P1, N=3, Completed, Sponsor: University of Oklahoma
Trial primary completion date: Mar 2018 --> Jun 2019 Recruiting --> Completed | N=15 --> 3
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) (clinicaltrials.gov) - Feb 19, 2019
P2, N=45, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Completed | N=15 --> 3 N=30 --> 45
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 16, 2019
P2, N=21, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 45 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial suspension: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Feb 15, 2019
P3, N=200, Suspended, Sponsor: Academic and Community Cancer Research United
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 N=910 --> 200 | Trial completion date: Jun 2020 --> Jun 2019 | Active, not recruiting --> Suspended
- || Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: ERASING: Eribulin in Advanced Solitary Fibrous Tumor (clinicaltrials.gov) - Feb 15, 2019
P2, N=16, Not yet recruiting, Sponsor: Italian Sarcoma Group
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Feb 11, 2019
P2, N=9, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=910 --> 200 | Trial completion date: Jun 2020 --> Jun 2019 | Active, not recruiting --> Suspended Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018 Trial completion date: Aug 2021 --> Aug 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment closed: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=88, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Aug 2021 --> Aug 2020 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Feb 6, 2019
P2, N=83, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> May 2016 | Trial primary completion date: Jun 2017 --> May 2016